Idealpharma

The computed 12-month bankruptcy probability of Idealpharma is 1.8% (moderate). The annual accounts of Idealpharma for financial year 2025 show a net loss of 78% of the equity at the start of that year. The 2025 annual accounts show equity of €55,469 and a net result of -€193,427. Equity is growing by about 3.8% per year across the filed financial years. Its solvency ranks better than 18% of 12,626 sector peers (NACE 47, financial year 2025). The company has been active since 2004 and the Belgian Official Gazette contains no insolvency or warning signals.